Warts Clinical Trial - Human Papillomavirus (HPV) Vaccination vs. Placebo

Status Recruiting

Clinical Trial Summary

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Clinical Trial Description

Cutaneous warts are a common cause for medical office visits and are frequently encountered in dermatology practice. Despite their benign nature, cutaneous warts can be painful, disfiguring, persistent and may be associated with significant morbidity. Numerous therapeutic options are available, including local destruction, virucidal agents, topical and systemic antiproliferative medications, and immunotherapy. Unfortunately, no single therapy is uniformly effective, and patients often receive multiple courses of treatment (cryotherapy, curettage, Candida antigen injection, etc.) without improvement. An efficacious therapy for cutaneous warts is sorely needed and treatment with HPV vaccination is being increasingly reported. Notably, individual cases and case series have reported complete resolution of multiple treatment refractory warts after treatment with the quadrivalent HPV vaccine. Even more encouraging, a larger retrospective study of 30 patients found that up to 60% of patients had a complete or partial response after treatment with the HPV vaccine. Additional benefits of treatment with HPV vaccination include ease of use, less tissue destruction and pain, and the potential for less frequent medical office visits. Despite these promising preliminary data, a larger, randomized controlled study has yet to be performed. This will be a multi-center, double-blinded, randomized, placebo-controlled trial with 120 participants. Enrolled participants will be randomized to treatment with either HPV vaccination or placebo. Participants will receive injections with the 9-valent HPV vaccine or placebo at 0, 4, and 20 weeks and follow up until 24 weeks to determine their treatment response, quality of life and the safety and tolerability of HPV vaccination. ;

Study Design

Related Conditions & MeSH terms

Warts

Clinical Trial Details

NCT number	NCT05625633
Study type	Interventional
Source	Western Institute for Veterans Research
Contact	Lowell Nicholson, MD
Phone	801-581-2121
Email	lowell.nicholson@hsc.utah.edu
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	March 25, 2024
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01757392` - Candin Safety & Efficacy Study for the Treatment of Warts	Phase 2
Completed	`NCT00973856` - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands	N/A
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Withdrawn	`NCT00546611` - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)	Phase 1
Completed	`NCT00117871` - Study With a Topical Gel to Treat Common Warts in Adults	Phase 2
Completed	`NCT04278573` - Intralesional Vitamin D Injection for Treatment of Common Warts	Phase 2
Completed	`NCT02231879` - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome	Phase 2/Phase 3
Completed	`NCT06309420` - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts	N/A
Not yet recruiting	`NCT05617950` - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts	N/A
Not yet recruiting	`NCT05616078` - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts	N/A
Recruiting	`NCT01712295` - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts	Phase 4
Active, not recruiting	`NCT00254280` - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial	N/A
Completed	`NCT04781244` - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment	N/A
Completed	`NCT01101750` - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?	Phase 4
Completed	`NCT03487549` - Cantharidin and Occlusion in Verruca Epithelium	Phase 2
Completed	`NCT02393417` - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)	Phase 2
Completed	`NCT01808443` - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts	N/A
Completed	`NCT00116662` - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects	Phase 2
Completed	`NCT00116675` - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects	Phase 2
Completed	`NCT00114920` - Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms